BRIDGEBIO PHARMA

Clinical Trial · Infigratinib · PROPEL · QED Therapeutics

BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia

SOURCE: BridgeBio Pharma, Inc.; The New England Journal of Medicine – In Cohort 5 of PROPEL 2, daily oral treatment of infigratinib at 0.25mg/kg resulted in statistically significant and sustained…

Read More BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
Achondroplasia · QED Therapeutics

BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia

The Chandler Project was honored to be part of the task force that helped develop MyAchonJounrey.com, which launched today! My Achon Journey provides guidance on navigating medical topics, psychosocial issues,…

Read More BridgeBio Launches MyAchonJourney, a New Resource for Families Navigating Achondroplasia
ACCEL · Achondroplasia · Clinical Trial · Infigratinib · PROPEL · QED Therapeutics

BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

SOURCE: Bridge Bio, Inc. QED Therapeutics, an affiliate company of BridgeBio, is an Emerald Sponsor of this year’s Achondroplasia & Skeletal Dysplasia Research Conference, June 28-30 in Baltimore, Maryland. This…

Read More BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

translate 🔁